The Series C financing will support the advancement of innovative oncology drug candidates through early clinical trials. Credit: Aunt Spray/Shutterstock.com.
Accent Therapeutics has announced the successful completion of a $75m Series C financing round to progress the development of small molecule precision cancer therapies.
The round was spearheaded by Mirae Asset Capital Life Science and saw contributions from new investors including Mirae Asset Capital, Mirae Asset Venture Investment, Bristol Myers Squibb and Johnson & Johnson Innovation.
Mirae Asset Capital Life Science managing director Naveen Krishnan will become part of Accent’s board of directors.
Accent’s lead candidate, a DHX9 inhibitor, is aimed at treating cancers with significant unmet medical needs, such as those associated with breast cancer gene (BRCA) loss of function (breast and ovarian cancers) and mismatch repair deficiency (colorectal, endometrial and gastric cancers).
Accent Therapeutics CEO Shakti Narayan stated: “We are delighted to announce the backing of an exceptional investor syndicate [that shares] our commitment to advancing innovative therapies for patients with cancer.
“These additional resources position us well to file INDs [investigational new drug applications] this year for both our DHX9 and KIF18A programmes, and to rapidly progress them through early clinical development.”